Remogliflozin etabonate

DB12935InvestigationalSmall molecule

Remogliflozin etabonate has been used in trials studying the treatment and basic science of Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2.

Chemical structure of Remogliflozin etabonate
Mechanism
Curator reviewed
Formula / weight
C26H38N2O9 · 522.595 g/mol (avg)
Code names
GSK-189075 · GSK-189075A

Resolves to

Compound
UNIITR0QT6QSULCAS442201-24-3ChEMBLCHEMBL2028665PubChem9871420
Structure
InChIKeyUAOCLDQAQNNEAX-ABMICEGHSA-NSMILESCCOC(=O)OC[C@H]1O[C@@H](OC2=NN(C(C)C)C(C)=C2CC2=CC=C(OC(C)C)C=C2)[C@H](O)[C@@H](O)[C@@H]1O
Targets
P31639SLC5A2Q9NY91SLC5A4

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
609Drug interactionsStructured to mechanism, not free text
Sign in
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Remogliflozin etabonate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In